Alan Carr

FCC Has No Authority To Block Elon Musk's Twitter Purchase, Commissioner Carr Says

Moderna Analysts Discuss Adcom Verdict, Distribution And Commercialization Of Coronavirus Vaccine

Moderna Analyst Positive On Coronavirus Vaccine Progress, Downgrades Shares On Valuation

Moderna Analysts Discuss Adcom Verdict, Distribution And Commercialization Of Coronavirus Vaccine

Moderna Analyst Positive On Coronavirus Vaccine Progress, Downgrades Shares On Valuation

Moderna Analysts On Positive Coronavirus Vaccine Data, Revenue Potential

Moderna Bull, Bear On Q3 Report, Coronavirus Vaccine Timeline

Moderna Analysts On Positive Coronavirus Vaccine Data, Revenue Potential

Moderna Bull, Bear On Q3 Report, Coronavirus Vaccine Timeline

9 Biotech Stocks With Material Catalysts In Q4

Moderna Analyst On Why Coronavirus Vaccine Developer's Stock Is Long-Term Attractive

Alan Carr Recent News

3 Moderna Analyst Takes On The Coronavirus Vaccine Developer's Pipeline

Coronavirus vaccine developer Moderna Inc (NASDAQ: MRNA) held a virtual R&D event Thursday, showcasing its portfolio and key therapeutics areas.

Gilead Analysts Downplay Q2 Miss Amid Remdesivir's COVID-19 Opportunity

Gilead Sciences, Inc. (NASDAQ: GILD) reported second-quarter revenues and earnings that trailed expectations. The Gilead Analysts

Needham Incrementally Bullish On Cara Therapeutics After CR845 Meets Endpoints

2 Reasons Vertex Pharmaceuticals Just Got Upgraded

Analysts Positive On Intercept Pharmaceuticals After Earnings, Pipeline Update

JMP, Needham Doubtful Over Chelsea Therapeutics Receiving Additional Bids

ISIS Pharmaceuticals, Inc. (ISIS) Maintains A Buy Rating